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Neurodegenerative parkinsonian syndromes comprise a number of disorders that are
characterized by similar clinical features but are separated on the basis of different
pathologies, i.e., aggregates of α-synuclein or tau protein. Due to the overlap of
signs and symptoms a precise differentiation is often difficult, especially early in the
disease course. Enormous efforts have been taken to develop tau-selective PET
imaging agents, but strong off-target binding to monoamine oxidase B (MAO-B) has
been observed across first generation ligands. Nonetheless, astrogliosis-related MAO-B
elevation is a common histopathological known feature of all parkinsonian syndromes
and might be itself an interesting imaging target. Therefore, this study aimed to
investigate the performance of [18F]-THK5351, a combined MAO-B and tau tracer for
differential diagnosis of parkinsonian syndromes. [18F]-THK5351 PET was performed in
34 patients: six with Parkinson’s disease (PD), nine with multiple system atrophy with
predominant parkinsonism (MSA-P), six with MSA with predominant cerebellar ataxia
(MSA-C), and 13 with progressive supranuclear palsy (PSP) Richardson’s syndrome.
Volume-of-interest-based quantification of standardized-uptake-values was conducted
in different parkinsonian syndrome-related target regions. PET results were subjected
to multinomial logistic regression to create a prediction model discriminating among
groups. Furthermore, we correlated tracer uptake with clinical findings. Elevated [18F]-
THK5351 uptake in midbrain and diencephalon differentiated PSP patients from PD and
MSA-C. MSA-C patients were distinguishable by high tracer uptake in the pons and
cerebellar deep white matter when compared to PSP and PD patients, whereas MSA-P
patients tended to show higher tracer uptake in the lentiform nucleus. A multinomial
logistic regression classified 33/34 patients into the correct clinical diagnosis group.
Tracer uptake in the pons, cerebellar deep white matter, and striatum was closely
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associated with the presence of cerebellar and parkinsonian symptoms of MSA
patients. The current study demonstrates that combined MAO-B and tau binding
of THK5351 facilitates differential diagnosis of parkinsonian syndromes. Furthermore,
our data indicate a correlation of MSA phenotype with [18F]-THK5351 uptake in
certain brain regions, illustrating their relevance for the emergence of clinical symptoms
and underlining the potential of THK5351 PET as a biomarker that correlates with
pathological changes as well as with disease stage.
Keywords: tau-PET, [18F]-THK5351, MAO-B, astrogliosis, parkinsonian syndromes
INTRODUCTION
Neurodegenerative parkinsonian syndromes comprise a number
of disorders that are grouped together due to similar clinical
features but are separated on the basis of different pathologies.
Depending on the type of abnormal protein depositions,
these disorders can histologically be divided into two groups:
synucleinopathies and tauopathies (Dickson, 2012). Parkinson’s
disease (PD) for example is characterized by intraneuronal
α-synuclein aggregates (Lewy bodies) (Dickson, 2018), whereas
the pathological hallmark of multiple system atrophy (MSA)
are α-synuclein positive oligodendroglial cytoplasmic inclusions.
A-Synuclein aggregates in MSA can be observed to a lesser extent
in the form of glial nuclear inclusions, neuronal cytoplasmic
inclusions, and neuronal nuclear inclusions (Papp and Lantos,
1992; Valera and Masliah, 2017). Progressive supranuclear
palsy (PSP) on the other hand is defined by deposition of
fibrillary aggregates of 4R tau-protein in neurons and glial cells
(Dickson et al., 2010).
Especially in the early course of the disease, a precise
differentiation of parkinsonian syndromes is often difficult
based on clinical features alone and misdiagnosis is a frequent
problem, with the most common misdiagnosis of PSP being PD
and MSA (Osaki et al., 2004). This is mainly due to clinical
heterogeneity and phenotypic overlap (McFarland, 2016). To this
day the definite diagnosis of neurodegenerative parkinsonian
syndromes still relies on post-mortem histological detection of
the underlying pathology.
Recent research in positron-emission-tomography (PET) has
focused on the development of tau-selective imaging agents that
allow regional quantification of tau burden. While molecular
imaging of tau deposits by PET initially focused on Alzheimer’s
disease, the most common tauopathy, an increasing number of
post-mortem and human studies are being conducted in 4R-
tau positive parkinsonian syndromes (Coakeley and Strafella,
2017; Schonhaut et al., 2017). However, substantial off-target
binding has been observed consistently, although with varying
Abbreviations: AUC, area under the curve; H&Y, Hoehn and Yahr stage;
MAO-B, monoamine oxidase B; MMSE, Mini-Mental State Examination; MSA,
multiple system atrophy; MSA-C, MSA with predominant cerebellar ataxia;
MSA-P, MSA with predominant parkinsonism; PD, Parkinson’s disease; PSP,
progressive supranuclear palsy; ROC, receiver operating characteristic; SEADL,
Schwab and England Activities of Daily Living scale; SUVR, standard-uptake-
value ratio; UMSARS, unified MSA Rating Scale; UMSARS-P/C, UMSARS-
parkinsonism/cerebellar features; VOI, volume-of-interest.
intensity, across most first generation tau radioligands (Brendel
et al., 2017; Saint-Aubert et al., 2017; Lemoine et al.,
2018; Vermeiren et al., 2018). Off-target binding to monoamine
oxidase B (MAO-B), which can be elevated due to concomitant
neuroinflammation and astrogliosis (Ekblom et al., 1993;
Rodriguez-Vieitez et al., 2016), has recently been shown for [18F]-
THK5351 (Ng et al., 2017; Harada et al., 2018). Therefore, [18F]-
THK5351 may be a suitable biomarker that does not specifically
indicate tau pathology but the localization of pathological
and neurodegenerative processes. Indeed, recent studies have
shown encouraging results regarding the use of [18F]-THK5351
for the differential diagnosis of PSP vs. HC and Alzheimer’s
disease (Brendel et al., 2017; Ishiki et al., 2017). A significantly
higher [18F]-THK5351 tracer retention could be detected in the
midbrain and globus pallidus of PSP patients.
The aim of this study was to investigate the potential of
combined MAO-B and tau binding of [18F]-THK5351 as a
tool for differential diagnosis of neurodegenerative parkinsonian
syndromes, i.e., PD, MSA, and PSP, in vivo. Furthermore,
we sought to correlate individual regional tracer uptake with
clinical phenotype and to compare PET results with magnetic
resonance imaging.
MATERIALS AND METHODS
Clinical Evaluation
A total of 34 patients from the outpatient clinic for
neurodegenerative diseases at the Departments of Neurology,
Ludwig-Maximilians-Universität München and Technical
University of Munich, Munich, Germany, were enrolled
in the study: 6 have been diagnosed with PD, 9 with MSA
with predominant parkinsonism (MSA-P), 6 with MSA with
predominant cerebellar ataxia (MSA-C), and 13 with PSP-
Richardson’s syndrome. The intake of MAO-B inhibitors was
excluded by taking the patients medication history. Diagnosis
was made according to current international consensus criteria
(Gilman et al., 2008; Postuma et al., 2015; Hoglinger et al.,
2017). PET results from 11/13 PSP patients have previously
been published (Brendel et al., 2017). Tight clinical follow-
up after initial diagnosis ensured the correctness of clinical
diagnosis (duration 23.4 ± 14.1 months, frequency every
3.9 ± 2.2 months). No adjustment of diagnosis was performed
due conflicting PET results. Disease severity was measured
with Hoehn and Yahr stage (H&Y). Furthermore, functional
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TABLE 1 | Demographic and clinical data of the study sample.
PD (n = 6) MSA-P (n = 9) MSA-C (n = 6) PSP (n = 13) p
Gender (m/f) 2/4 5/4 5/1 5/8 0.247
Age (y) 65.7 ± 8.1 68.1 ± 9.7 63.0 ± 9.1 69.2 ± 7.2 0.437
Education (y) 12.0 ± 3.8 11.8 ± 1.7 11.4 ± 0.9 12.6 ± 2.8 0.817
Disease duration (mo) 32.5 ± 30.3 44.4 ± 21.2 65.3 ± 69.3 33.7 ± 19.5 0.385
MMSE 29.4 ± 1.3 25.7 ± 4.2 28.3 ± 2.4 26.9 ± 1.5 0.072
H&Y 2.0 ± 1.5 2.8 ± 1.0 2.8 ± 1.5 3.4 ± 0.9 0.047
SEADL 76.7 ± 23.4 62.2 ± 22.8 65.0 ± 25.9 67.7 ± 16.4 0.496
For group comparisons a Kruskal–Wallis test and post hoc Bonferroni-corrected Mann–Whitney tests were performed. Chi-square analysis was used to test for differences
in gender distribution. PD, Parkinson’s disease; MSA-P, multiple system atrophy with predominant parkinsonism; MSA-C, multiple system atrophy with dominant cerebellar
features; PSP, progressive supranuclear palsy; m, male; f, female; y, years; mo, months; MMSE, Mini-Mental State Examination; H&Y, Hoehn and Yahr Stage; SEADL,
Schwab and England Activities of Daily Living scale.
independence was measured using the Schwab and England
Activities of Daily Living Scale (SEADL) and disease duration was
recorded. The cognitive state was assessed by the Mini-Mental
State Examination (MMSE). Written informed consent was
obtained by all participants in accordance with the Declaration
of Helsinki. Retrospective analysis of data had been approved by
the local ethics committee. Demographic features of participants
are listed in Table 1.
Generation of the UMSARS-P/C Score
MSA patients can present with a combination of both
parkinsonian and cerebellar features. As clinical phenotypes
have been shown to be associated with predominant
neurodegeneration and glial cytoplasmic inclusion pathology in
the striatonigral and olivopontocerebellar system, respectively
(Ozawa et al., 2004; Jellinger, 2014) we hypothesized that [18F]-
THK5351 tracer retention in these brain areas may correlate to
the amount of parkinsonian and cerebellar features.
The unified MSA rating scale (UMSARS) is the most
commonly used disease-specific rating instrument in MSA and
was developed to rate functional impairment independent of
the underlying motor disorder (Wenning et al., 2004). To
assess the amount of parkinsonian and cerebellar symptoms
in our MSA cohort we calculated from the UMSARS part
II, which was available in nine MSA patients, a new score
(UMSARS parkinsonism/cerebellar features, i.e., UMSARS-P/C).
To obtain a linear scale for correlation analysis the items facial
expression, tremor at rest and increased tone referring to specific
parkinsonian symptoms were scaled from 0 (no impairment)
to −4 (severe impairment) whereas the items ocular motor
dysfunction, action tremor, and heel–knee–shin test referring to
specific cerebellar symptoms were scaled from 0 (no impairment)
to +4 (severe impairment). All other items from the UMSARS
part II were not included in the generation of the UMSARS-
P/C score, as they measure functional impairment of complex
movements and can be caused by both parkinsonian and
cerebellar symptoms. Therefore, the UMSARS-P/C potentially
ranges from −12 representing severe pure parkinsonism to
+12 representing severe pure cerebellar symptoms. As most
MSA patients present with a combination of parkinsonian
and cerebellar features the score ranged from −4 to +4 in
our study cohort.
PET Imaging
Automated production of [18F]-THK5351 was performed on a
Raytest R© SynChrom R&D single reactor synthesizer as reported
previously (Brendel et al., 2017).
All emission recordings were performed in a previously
established protocol (Brendel et al., 2017). In brief, images were
acquired using a GE Discovery 690 PET/CT scanner. A prior low-
dose CT scan was performed for attenuation correction. Dynamic
three-dimensional emission recordings were acquired during an
interval of 50–70 min after intravenous injection of 183± 4 MBq
[18F]-THK5351.
The PNEURO data processing pipeline of PMOD Version
3.5 (PMOD Technologies Ltd., Zurich, Switzerland) was used
for spatial normalization of all [18F]-THK5351 images to the
Montreal Neurological Institute (MNI) space. All individual PET
images were spatially normalized to the previously established
[18F]-THK5351 template using the PMOD FUSION tool (equal
modality; non-linear warping; 16 iterations; frequency cutoff
3; regularization 1.0; no thresholding; 8 mm transient input
smoothing). Global mean intensity scaling was used for
image normalization.
For semiquantitative analyses, volume of interest (VOIs)
were predefined in target regions known to be affected by
MAO-B elevation and tau pathology in parkinsonian syndromes:
midbrain, diencephalon, striatum, nucleus lentiformis, pons, and
cerebellar deep white matter. Mean standard-uptake-value ratios
(SUVR) relative to the global mean (SUVRGLM) were calculated
for each VOI in all subjects.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) data were available in 26/34
patients. The remaining patients either refused MRI or had a
contraindication to MRI, e.g., permanent cardiac pacemakers.
In accordance with prior studies assessing morphometric MRI
parameters for differential diagnosis of parkinsonism (Cosottini
et al., 2007; Heim et al., 2017), we determined the ratio of
the midbrain cross-sectional area scaled by the pons area. All
measurements were performed in Horos open source medical
image viewer1 on mid-sagittal images of T1/T2w sequences.
A midsagittal plane of the brain volume passing through
1http://horosproject.org/
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the middle of the interpeduncular fossa, the middle of the
aqueduct, and the falx cerebri was chosen (each determined on
axial images). The midbrain area was determined by tracing
the contour of the midbrain down to a line parallel to the
hypothetic conjunction between the genu and splenium of the
corpus callosum touching the superior part of the pons. For
the determination of the pons midsagittal area, we used the
region underneath, extending from the lower bound of the
midbrain area down to a parallel line touching the inferior
border of the pons.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics for Windows
(Version 25.0., IBM Corp., Armonk, NY, United States). Non-
dichotomized mean scores of demographic and clinical data
were compared across the four groups (PD, MSA-P, MSA-C, and
PSP patients) via Kruskal–Wallis test and post hoc Bonferroni
corrected Mann–Whitney tests. Chi-square analysis was used
to test for differences in gender distribution across all groups.
Standard statistical significance level was set at p< 0.05.
For group comparisons of semiquantitative PET results in
different target VOIs a Kruskal–Wallis test was performed.
Significance levels for the Kruskal–Wallis test were adjusted
according to Bonferroni correction (p < 0.0083). Results
of post hoc tests were regarded significant if they survived
an additional Bonferroni correction for multiple pairwise
comparisons. Spearman’s test was used to explore significant
correlations between PET results and clinical parameters (H&Y,
SEADL, disease duration, UMSARS-P/C) and the midbrain-to-
pons area ratio calculated from MRI, respectively.
Four-category multinomial logistic regression was used
to classify among the four disease groups using significant
semiquantitative PET results as predictor variables. Additionally,
multinomial logistic regression using MRI midbrain-to-pons area
ratio as predictor was performed to compare the diagnostic utility
of [18F]-THK5351 PET and MRI.
RESULTS
Demographic and Clinical Data
Demographics and clinical scores of the study sample are
provided in Table 1. Patient groups did not differ significantly
in terms of age, gender, education, disease duration, MMSE,
and SEADL. Kruskal–Wallis test detected significant group
differences of H&Y stage with lowest scores in PD and
highest scores in PSP.
Regional PET Analyses
Significant differences of [18F]-THK5351 uptake were observed
in the diencephalon, midbrain, pons, and cerebellar deep white
matter (Kruskal–Wallis test, Table 2 and Figures 1A,B). [18F]-
THK5351 uptake in the lentiform nucleus was highest in
MSA-P patients but did not survive the significance threshold
for multiple comparisons. No significant differences could be
detected for the striatum.
Post hoc Bonferroni tests showed that PSP patients had
higher [18F]-THK5351 uptake in the diencephalon compared
to PD and MSA-C and had higher [18F]-THK5351 uptake in
the midbrain compared to all other patient groups whereas
MSA-C patients had higher [18F]-THK5351 uptake in the pons
compared to PSP and PD patients and had higher [18F]-THK5351
uptake in cerebellar deep white matter compared to PSP patients
(Figures 1A,B).
Logistic Regression
The multinomial logistic regression model was able to accurately
classify 33/34 (97.1%) patients using the [18F]-THK5351 uptake
in the diencephalon, midbrain, pons, and cerebellar deep white
matter as predictor variables (p < 0.05, R2 = 0.98). A more
conservative and therefore potentially clinically more meaningful
regression model using only the [18F]-THK5351 uptake in the
midbrain and pons as predictor variables was still able to
correctly classify 29/34 (85.3%) patients (p < 0.05, R2 = 0.93).
A model using the MRI midbrain-to-pons area ratio as predictor,
however, was able to accurately classify 17/26 (65.4%) patients
(p< 0.05, R2 = 0.68).
Correlation Analysis
In order to assess the potential of [18F]-THK5351 as a biomarker
of disease stage and progression, a correlation analysis of tracer
uptake and clinical parameters as well as with MRI atrophy
was conducted. We observed a significant positive correlation of
H&Y stage with [18F]-THK5351 uptake in the lentiform nucleus
(rs = 0.38, p = 0.03), the midbrain (rs = 0.53, p = 0.001), and the
diencephalon (rs = 0.42, p = 0.01) and a negative correlation of
TABLE 2 | [18F]-THK5351 uptake.
PD MSA-P MSA-C PSP p
Striatum 2.24 ± 0.26 2.38 ± 0.21 2.31 ± 0.15 2.47 ± 0.16 0.101
Lentiform nucleus 1.83 ± 0.17 2.25 ± 0.38 2.05 ± 0.36 2.00 ± 0.11 0.042
Diencephalon 1.81 ± 0.22d 1.88 ± 0.25 1.87 ± 0.14d 2.16 ± 0.15a,c 0.005
Midbrain 1.66 ± 0.09d 1.66 ± 0.13d 1.76 ± 0.08d 2.09 ± 0.22a,b,c <10−4
Pons 1.41 ± 0.18c 1.75 ± 0.36 2.33 ± 0.30a,d 1.62 ± 0.13c 0.001
Cerebellar deep white matter 1.10 ± 0.10 1.30 ± 0.29 1.77 ± 0.32d 1.16 ± 0.07c 0.006
[18F]-THK5351 uptake: Mean standard-uptake-value ratios relative to the global mean. For group comparisons a Kruskal–Wallis test and post hoc Mann–Whitney tests
were performed. Significance levels of both tests were adjusted according to Bonferroni correction (p < 0.0083). PD, Parkinson’s disease; MSA-P, multiple system atrophy
with predominant parkinsonism; MSA-C, multiple system atrophy with dominant cerebellar features; PSP, progressive supranuclear palsy. Significantly different compared
to aPD, bMSA-P, cMSA-C, and dPSP.
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FIGURE 1 | [18F]-THK5351 tracer uptake. (A) High midbrain uptake in axial and sagittal slices allows visual discrimination of the PSP patient group from other
patient groups. Significantly higher [18F]-THK5351 uptake in the diencephalon was detected in PSP patients compared to PD and MSA-C patients. In contrast, in
MSA-C patients, but not in MSA-P patients, [18F]-THK5351 uptake was especially high in the pons and cerebellar deep white matter. (B) Tracer uptake in the
midbrain, pons, diencephalon, and cerebellar deep white matter. ∗ indicates significant differences.
the SEADL with [18F]-THK5351 uptake in the lentiform nucleus
(rs =−0.49, p = 0.003) and pons (rs =−0.43, p = 0.01). There was
no significant correlation of tracer uptake with disease duration.
As clinical variants of MSA are known to be associated
with morphologic phenotypes of striatonigral and
olivopontocerebellar degeneration an additional correlation
analysis of regional [18F]-THK5351 tracer uptake and the
amount of parkinsonian and cerebellar features measured by
the UMSARS-P/C was performed. The UMSARS-P/C was
positively correlated with tracer uptake in the pons (rs = 0.92,
p = 0.001) and cerebellar deep white matter (rs = 0.75, p = 0.02)
and negatively correlated with tracer uptake in the striatum
(rs = −0.71, p = 0.03) (Figures 2A,B). Figure 2B demonstrates
tracer uptake of patients with an UMSARS-P/C score of −4, −2,
0,+2, and+4 in these regions.
The MRI midbrain-to-pons area ratio showed a positive
correlation with [18F]-THK5351 uptake in the pons (rs = 0.49,
p = 0.01) and cerebellar deep white matter (rs = 0.47, p = 0.02)
and a negative correlation with tracer uptake in the diencephalon
(rs =−0.54, p = 0.01) and midbrain (rs =−0.42, p = 0.03).
DISCUSSION
We present the first study demonstrating the value of a
combined MAO-B and tau radioligand for the differential
diagnosis of neurodegenerative parkinsonian syndromes
including primary tauopathies (PSP) and α-synucleinopathies
(PD, MSA). Tracer uptake levels of [18F]-THK5351 in the
diencephalon, midbrain, pons, and cerebellar deep white matter
are significant predictors of clinical diagnosis. Furthermore,
our data indicate a strong association between region-specific
tracer uptake and the amount of parkinsonian and cerebellar
symptoms in MSA.
In recent years, enormous efforts have been taken to develop
tau-selective PET imaging agents (Xia et al., 2013; Okamura
et al., 2014). First generation tau PET tracers like [18F]-AV1451
and [18F]-THK5351 have shown in PSP patients high tracer
uptake in regions that are known from histological examination
post mortem to be severely affected by tau pathology in PSP
(Williams et al., 2007; Dickson et al., 2010). However, substantial
off-target binding has been observed for all first generation tau-
tracers. [18F]-AV1451 for example shows significant off-target
binding to neuromelanin-containing cells from the substantia
nigra, vascular structures like the choroid plexus and dural
venous sinuses, and the basal ganglia in general (Marquie
et al., 2015; Lowe et al., 2016) whereas [18F]-THK5351 has
been shown to bind to MAO-B. In a recent human blocking
study a single oral dose of 5 mg of selegiline has led to a
reduction of [18F]-THK5351 retention of up to 51.8% (Ng
et al., 2017). Furthermore, imaging-pathology studies of autopsy-
confirmed patients who underwent [18F]-THK5351 PET before
death showed a significant correlation between in vivo [18F]-
THK5351 uptake and post mortem MAO-B levels (Harada et al.,
2018; Ishiki et al., 2018). These results suggest a high amount of
tracer retention being due to binding to MAO-B.
MAO-B catalyzes the oxidative deamination of biogenic
amines like dopamine. As MAO-B is mainly located in the
mitochondrial outer membrane of astrocytes (Shih et al., 1999),
especially reactive astrocytes, it has been proposed as a marker
of astrogliosis (Ekblom et al., 1993; Rodriguez-Vieitez et al.,
2016). A recent post mortem study in parkinsonian conditions
showed elevated MAO-B levels in the putamen and midbrain of
MSA patients, elevated MAO-B levels in the caudate nucleus,
Frontiers in Aging Neuroscience | www.frontiersin.org 5 September 2019 | Volume 11 | Article 249
fnagi-11-00249 September 10, 2019 Time: 16:3 # 6
Schönecker et al. [18F]-THK5351 PET in Parkinsonian Syndromes
FIGURE 2 | Correlation of [18F]-THK5351 tracer uptake with UMSARS-P/C: (A) Correlation of [18F]-THK5351 tracer uptake in the pons, cerebellar deep white matter,
and striatum with UMSARS-P/C. (B) Axial and sagittal slices showing individual tracer uptake of patients with an UMSARS-P/C score of –4, –2, 0, +2, and +4.
putamen, and midbrain of PSP patients but no elevation of
MAO-B in the basal ganglia of PD patients (Tong et al., 2017).
Furthermore, MAO-B was positively correlated to astrocyte
proteins like vimentin, HSP27, and glial fibrillary acid protein.
Hence, MAO-B in the atypical parkinsonian syndromes MSA
and PSP was significantly increased in brain areas affected
by neurodegeneration.
MAO-B off target binding brought [18F]-THK5351 into
disrepute during the last 2 years. Nonetheless, the opportunity
to assess both astrogliosis and tau pathology by a single
in vivo examination has several major advantages as proven
by the current data: First, neuropathological features of both
tauopathies (astrogliosis and tau) and α-synucleinopathies
(astrogliosis) can be assessed by a positive contrast. In particular
a pure tau tracer would not be able to detect MSA or PD
patients, whereas a pure α-synuclein ligand would blind to
PSP. Second, the varying topology of neuropathology allows
to discriminate clinically similar parkinsonian syndromes with
different underlying proteinopathies. Third, astrogliosis has been
shown to be an early biomarker in the time course of Alzheimer’s
disease (Rodriguez-Vieitez et al., 2016; Rodriguez-Vieitez and
Nordberg, 2018) which might also be the case for parkinsonian
syndromes, allowing an early discrimination.
As expected from our previous comparison of PSP patients
against healthy controls (Brendel et al., 2017), a significantly
higher [18F]-THK5351 uptake in the midbrain of PSP patients
compared to all other patient groups was observed, a region that
is known to be affected by both increased MAO-B levels (Tong
et al., 2017) and tau pathology (Dickson et al., 2010) in PSP.
In the diencephalon, a region in which tau-pathology in PSP
is also abundant (Williams et al., 2007; Dickson et al., 2010),
a significantly higher tracer uptake could be detected in PSP
compared to PD and MSA-C, while tracer uptake also showed a
trend toward significance in comparison to MSA-P (p = 0.015).
In contrast, no significant group differences concerning tracer
uptake could be detected in the striatum. In the lentiform
nucleus, that is composed of putamen and globus pallidus, tracer
uptake was highest in MSA-P patients, followed by MSA-C and
PSP patients, but did not survive the significance threshold for
multiple comparisons. This is probably due to the combination
of elevated MAO-B levels and tau pathology in the putamen of
PSP patients and the fact that MAO-B levels have been shown to
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be highly increased in MSA patients (Tong et al., 2017). Tracer
uptake in the lentiform nucleus was lowest in the PD patient
group which is in good agreement with the fact that MAO-B
levels have been shown to be normal and astrogliosis to be limited
in the basal ganglia of PD patients (Song et al., 2009).
In MSA-C pontine [18F]-THK5351 uptake was significantly
elevated when compared to PSP and PD patients and was also
elevated when compared to MSA-P but did not survive the
significance threshold for multiple comparisons (p = 0.013).
Furthermore, tracer uptake in the cerebellar deep white matter
of MSA-C patients was increased in comparison to PSP
patients and showed a trend toward significance in comparison
to PD (p = 0.010) and MSA-P (p = 0.077) patients. Both
regions are known to be early foci of α-synuclein pathology
in MSA-C (Brettschneider et al., 2017). Recent studies have
shown that astrogliosis in MSA and thereby increased MAO-
B levels correlate to the presence of oligodendrocytes with
α-synuclein glial cytoplasmic inclusions (Radford et al., 2015).
This fact suggests that localized presence of α-synuclein
underlies astrocytic pathology in MSA and explains the high
amount of tracer uptake detected in our MSA-C patient group
in these regions.
Due to the overlap of signs and symptoms of parkinsonian
syndromes a reliable diagnosis remains a major clinical challenge.
However, diagnostic accuracy is essential for estimation of
prognosis, optimizing patient care, and allocation to therapeutic
trials. While the accuracy of PD diagnosis in movement disorders
centers has been shown to be almost 99%, the diagnostic accuracy
of atypical parkinsonian syndromes is limited being only 77%
(Hughes et al., 2002). When the diagnosis is made by general
neurologists diagnostic accuracy is even worse being 75 and
61%, respectively (Joutsa et al., 2014). Imaging modalities may
help to increase diagnostic certainty. In our current study
the optimal multinomial logistic regression model was able to
accurately classify 33/34 patients using [18F]-THK5351 uptake
in the diencephalon, midbrain, pons, and cerebellar deep white
matter as predictor variables. A more conservative and therefore
potentially clinically more meaningful model using only tracer
uptake in the midbrain and pons as predictors was still able
to classify 85.3% of patients correctly. Previous studies have
shown good diagnostic accuracy of MRI midbrain-to-pons area
ratio for differentiating patients with PSP from patients with
MSA and PD (Cosottini et al., 2007; Moller et al., 2017).
A multinomial logistic regression model using the midbrain-
to-pons area ratio as predictor variable, however, only led to a
classification accuracy of 65.4% and was therefore worse than
the model using semiquantitative PET results as predictors. Our
data therefore provide evidence for [18F]-THK5351 uptake in the
diencephalon, midbrain, pons, and cerebellar deep white matter
to be of high predictive value in diagnosing the four parkinsonian
syndromes under investigation. Combined MAO-B and tau
binding of [18F]-THK5351 seems to be of value for differentiation
of parkinsonian syndromes and may be a useful diagnostic tool in
the absence of 4R-tau- and α-synuclein-selective ligands.
In order to evaluate therapeutic agents, biomarkers that
correlate with pathological changes as well as with clinical
phenotype are urgently needed. To be clinically relevant the
respective biomarker must therefore show a good correlation
with disease stage and progression and may then be used for
the evaluation of therapeutic responses (Frank and Hargreaves,
2003). Recent studies, including our group, have detected a
significant correlation between the intensity of [18F]-THK5351
and [18F]-AV1451 tracer uptake in the midbrain and disease
severity measured by the PSP Rating Scale in PSP patients
(Brendel et al., 2017; Whitwell et al., 2017). In our MSA cohort
tracer uptake in the striatum, pons, and cerebellar deep white
matter correlated with the amount of parkinsonian and cerebellar
symptoms, respectively. This finding illustrates the clinical
relevance of the striatum for the emergence of parkinsonian
symptoms and the relevance of the pons and cerebellar deep
white matter for the emergence of cerebellar symptoms in
MSA and underlines the potential of [18F]-THK5351 PET as a
biomarker assessing phenotype and disease stage.
Furthermore, our data disclosed a positive/negative
correlation between midbrain-to-pons area ratio calculated
from MRI with [18F]-THK5351 uptake in the pons and
cerebellar deep white matter as well as with tracer uptake in
the diencephalon and midbrain. This correlation is driven by
the combined effect of pontine atrophy in MSA-C patients
that show a high amount of tracer uptake in the pons and
cerebellar deep white matter and midbrain atrophy in PSP
patients that have significantly higher tracer uptake in the
diencephalon and midbrain. Therefore, [18F]-THK5351
retention seems to be closely related to other markers of neuronal
injury. This finding suggests that the presence of astrogliosis-
related MAO-B elevation and tau, respectively, strongly
affects neurodegeneration and assures us about well-capturing
neuropathological changes.
A limitation of the current study that needs to be considered
is the absence of a neuropathological confirmation of diagnosis
which reflects the moderate clinical severity within our patients,
most of whom are alive at the time being. However, the
lack of a neuropathological confirmation is a general problem
in studies investigating neurodegenerative disorders at an
early disease stage. Therefore, there remains the possibility
that some cases had a mismatch of clinical diagnosis and
underlying pathology. However, the present results have face
validity given the agreement between [18F]-THK5351 uptake
and the known topology of tau distribution in PSP patients
and the topology of astrogliosis in the patient groups under
investigation, respectively. Furthermore, the tight clinical follow-
up over 23.4 ± 14.1 months ensured us about the clinical
diagnosis. Furthermore, a more deep and specific cognitive
assessment would have been desirable. However, as the current
study is retrospective by nature, this was not feasible. We
further acknowledge the small sample size, especially of MSA-
C patients. However, it should be noted that the current
study is the first investigating [18F]-THK5351 uptake in
MSA. Nonetheless a larger multicenter investigation of this
rare disease will be needed to evaluate the utility of [18F]-
THK5351 as a combined radiotracer of tau and astrogliosis in
neurodegenerative diseases.
Keeping these limitations in mind our findings reveal
combined tau and MAO-B binding of [18F]-THK5351
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to facilitate differential diagnosis of neurodegenerative
parkinsonian syndromes and to correlate with phenotype and
MRI atrophy. [18F]-THK5351 may have limited utility as a
specific biomarker of tau but may be a promising marker of
neuroinflammation accompanying neurodegeneration.
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